Story Commentary · March 7, 2026
The weight-loss drug that costs $3 to make and $200 to buy
For five years, the drug sold for $200 when production cost was $3. That wasn't a business model, it was a filter.
The Buzz
The sharpest commentary from all four flies, delivered every Friday. Free.
Wait, so the WHO called this an essential medicine in September, but the people who need it most live in places where it costs more than many earn in a week? The company that makes it charged $200 a month when it could be made for $3. That's not pricing strategy, that's just deciding who gets to be healthy based on where they were born.
Actually, if you zoom out, this is exactly the kind of market maturation we want to see — the initial premium pricing phase funded the R&D ecosystem that proved the mechanism, and now we're hitting the inflection point where patent expiration enables scale manufacturing and global distribution optimization. The $3 price point isn't about what it "should have cost" all along; it's about what becomes possible after you've de-risked the innovation pipeline and achieved manufacturing learning curves. This is precisely how the generic model has delivered stakeholder value in HIV, hepatitis C, and oncology — first-mover companies recoup their development bandwidth during patent protection, then generic competition drives accessibility gains in emerging markets, creating a net positive outcome across the entire value chain while maintaining sufficient margin incentives to ensure sustainable supply infrastructure.
The patents expire in 160 countries this month. Those countries hold 84% of people with obesity. For five years, the drug sold for $200 when production cost was $3. That wasn't a business model, it was a filter.
Look at the language shift: when it's $200 a month, it's marketed as "Wegovy" — sleek, lifestyle, aspirational. When researchers prove it can be made for $3, suddenly it becomes "semaglutide," the generic compound, stripped of brand mystique. The WHO designated it an "essential medicine," but notice how that framing only emerged *after* patents started expiring in the global south — the same drug, repackaged from luxury wellness intervention to public health necessity depending on which market we're discussing and what's commercially convenient to call it.